Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00347919. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination With Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects With Advanced or Metastatic Breast Cancer With ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the ErbB2 protein.
Study identification
- NCT ID
- NCT00347919
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 189 participants
Conditions and interventions
Conditions
Interventions
- pazopanib (GW786034) 400 mg Drug
- lapatinib (GW572016) 1500 mg Drug
- lapatinib (GW572016) 1000 mg Drug
- pazopanib (GW786034) 800 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2006 (Type not available)
- Primary completion
- Aug 2008 (Actual)
- Completion
- Mar 2015 (Actual)
- Last update posted
- Feb 25, 2016
2006 – 2015
United States locations
- U.S. sites
- 19
- U.S. states
- 8
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Jonesboro | Arkansas | 72401 | — |
| GSK Investigational Site | Alhambra | California | 91801 | — |
| GSK Investigational Site | Bakersfield | California | 93309 | — |
| GSK Investigational Site | Fullerton | California | 92835 | — |
| GSK Investigational Site | Long Beach | California | 90813 | — |
| GSK Investigational Site | Los Angeles | California | 90095-1752 | — |
| GSK Investigational Site | Northridge | California | 91328 | — |
| GSK Investigational Site | Oxnard | California | 93030 | — |
| GSK Investigational Site | Redondo Beach | California | 90277 | — |
| GSK Investigational Site | Santa Barbara | California | 93105 | — |
| GSK Investigational Site | Santa Maria | California | 93454 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46202 | — |
| GSK Investigational Site | Metairie | Louisiana | 70006 | — |
| GSK Investigational Site | Henderson | Nevada | 89052 | — |
| GSK Investigational Site | The Bronx | New York | 10461 | — |
| GSK Investigational Site | Akron | Ohio | 44304 | — |
| GSK Investigational Site | Dallas | Texas | 75390-9113 | — |
| GSK Investigational Site | Lubbock | Texas | 79410 | — |
| GSK Investigational Site | San Antonio | Texas | 78207 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00347919, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 25, 2016 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00347919 live on ClinicalTrials.gov.